Your browser is no longer supported. Please, upgrade your browser.
Settings
ALNY Alnylam Pharmaceuticals, Inc. daily Stock Chart
ALNY [NASD]
Alnylam Pharmaceuticals, Inc.
Index- P/E- EPS (ttm)-5.87 Insider Own0.40% Shs Outstand95.97M Perf Week-1.88%
Market Cap8.75B Forward P/E- EPS next Y-6.85 Insider Trans-43.64% Shs Float89.08M Perf Month-10.80%
Income-570.70M PEG- EPS next Q-1.95 Inst Own90.80% Short Float5.62% Perf Quarter-10.21%
Sales106.80M P/S81.97 EPS this Y-13.10% Inst Trans-3.08% Short Ratio6.68 Perf Half Y-23.97%
Book/sh16.12 P/B5.66 EPS next Y2.60% ROA-32.30% Target Price149.40 Perf Year13.50%
Cash/sh15.08 P/C6.05 EPS next 5Y46.09% ROE-36.80% 52W Range70.76 - 153.99 Perf YTD-28.20%
Dividend- P/FCF- EPS past 5Y-20.80% ROI- 52W High-40.76% Beta2.46
Dividend %- Quick Ratio13.20 Sales past 5Y6.10% Gross Margin- 52W Low28.91% ATR4.11
Employees749 Current Ratio13.20 Sales Q/Q88.10% Oper. Margin- RSI (14)37.89 Volatility3.87% 4.23%
OptionableYes Debt/Eq0.02 EPS Q/Q-21.10% Profit Margin- Rel Volume1.40 Prev Close93.18
ShortableYes LT Debt/Eq0.02 EarningsAug 02 BMO Payout- Avg Volume749.98K Price91.22
Recom2.10 SMA20-7.47% SMA50-9.52% SMA200-20.52% Volume1,051,166 Change-2.10%
Aug-13-18Reiterated Stifel Buy $125 → $123
Aug-07-18Upgrade Stifel Hold → Buy $95 → $125
May-04-18Reiterated Stifel Hold $107 → $95
Mar-28-18Initiated Evercore ISI In-line
Mar-26-18Reiterated JMP Securities Mkt Outperform $169 → $207
Feb-16-18Reiterated B. Riley FBR, Inc. Buy $205 → $200
Jan-08-18Reiterated B. Riley FBR, Inc. Buy $220 → $205
Nov-09-17Upgrade JP Morgan Neutral → Overweight
Nov-08-17Reiterated Barclays Overweight $127 → $158
Nov-08-17Reiterated B. Riley FBR, Inc. Buy $240 → $220
Nov-03-17Reiterated Needham Buy $125 → $152
Nov-02-17Reiterated B. Riley FBR, Inc. Buy $150 → $240
Oct-30-17Initiated FBR & Co. Buy $150
Oct-02-17Upgrade Goldman Neutral → Buy
Sep-21-17Reiterated Needham Buy $85 → $125
Sep-15-17Initiated Instinet Reduce
Jun-22-17Resumed Jefferies Buy $102
May-15-17Reiterated Chardan Capital Markets Buy $95 → $110
Mar-30-17Initiated UBS Neutral $55
Feb-09-17Reiterated Needham Buy $98 → $68
Aug-15-18 01:41PM  Akcea Therapeutics Soars as It Readies Its First Drug Launch Motley Fool
08:56AM  3 Hurdles Ahead of Alnylam and Its Revolutionary New Drug Motley Fool
Aug-13-18 10:20PM  Alnylam drug approval marks watershed moment for gene-silencing field American City Business Journals -6.60%
09:55PM  Edited Transcript of ALNY earnings conference call or presentation 2-Aug-18 12:30pm GMT Thomson Reuters StreetEvents
05:12PM  What Happened in the Stock Market Today Motley Fool
03:49PM  Nobel Winner on Alnylams Breakthrough Gene-Muting Therapy Bloomberg
02:19PM  Scientists Cracked a Deadly DNA Puzzle. Then Came the Hard Part Bloomberg
02:14PM  Goldman Drops Alnylam From Conviction List, But Continues To See 'Blockbuster Potential' Benzinga
10:51AM  Alnylam (ALNY) Gets FDA Nod for First-Ever RNAi Therapeutic Zacks
09:37AM  [$$] Stocks to Watch: Alphabet, Netflix, Nielsen, Alnylam, Qualcomm The Wall Street Journal
08:30AM  Arbutus LNP Licensee Alnylam Announces FDA Approval of ONPATTRO (patisiran), for the Treatment of ATTR Amyloidosis GlobeNewswire
08:00AM  Today's Research Reports on Trending Tickers: Spectrum Pharmaceuticals and Alnylam Pharmaceuticals ACCESSWIRE
Aug-11-18 10:04AM  Alnylam rare drug gets FDA approval, to cost $345,000 on average MarketWatch
Aug-10-18 07:49PM  New Kind of Drug, Silencing Genes, Gets FDA Approval The Wall Street Journal
05:09PM  Alnylam's gene silencing drug wins FDA approval Reuters
04:03PM  Alnylam Makes History With Approval Of RNA Therapy Benzinga
02:37PM  Alnylam Announces Alignment on Value-Based Agreements with Leading Health Insurers and Launches Comprehensive Patient Support Services for ONPATTRO (patisiran) Business Wire
02:28PM  Alnylam Announces First-Ever FDA Approval of an RNAi Therapeutic, ONPATTRO (patisiran) for the Treatment of the Polyneuropathy of Hereditary Transthyretin-Mediated Amyloidosis in Adults Business Wire
02:17PM  FDA Approves First Drug Based on 'Gene-Silencing' Research The Wall Street Journal
01:44PM  Rare-Disease Treatment From Alnylam Will Cost $450,000 a Year Bloomberg
01:08PM  Alnylam's gene silencing drug wins FDA approval Reuters
12:59PM  Cambridge biotech Alnylam wins FDA approval for first drug American City Business Journals
07:38AM  The Daily Biotech Pulse: Puma, CareDx Soar On Earnings, Corcept Plunges On Bottom-Line Miss Benzinga
Aug-09-18 10:15AM  7 Biotech Stocks With Big Upcoming Catalysts Kiplinger
Aug-07-18 05:50AM  As FDA decision looms, Alnylam triples Kendall footprint, plans to double staff American City Business Journals
Aug-06-18 06:22PM  Alnylam Pharmaceuticals (ALNY) Q2 2018 Earnings Conference Call Transcript Motley Fool
01:09PM  Alnylam Pharmaceuticals Is "Launch Ready" Motley Fool
11:40AM  Alnylam's (ALNY) Q2 Loss Wider Than Expected, Sales Beat Zacks
Aug-05-18 09:44AM  The Week Ahead In Biotech: Conferences, PDUFA Dates And IPOs Benzinga
Aug-03-18 07:00AM  Alnylam Announces that the United Kingdoms MHRA Grants Early Access to Patisiran Business Wire
Aug-02-18 10:50AM  Alnylam Pharmaceuticals (ALNY) Reports Q2 Loss, Tops Revenue Estimates Zacks
09:48AM  Alnylam: 2Q Earnings Snapshot Associated Press
08:00AM  Alnylam Pharmaceuticals Reports Second Quarter 2018 Financial Results and Highlights Recent Period Activity Business Wire
06:30AM  Alnylam Pharmaceuticals, Inc to Host Earnings Call ACCESSWIRE
Aug-01-18 07:38AM  Attention Biotech Investors: Mark Your Calendar For These August PDUFA Dates Benzinga
Jul-31-18 07:15AM  Blog Exposure - CHMP Adopts Positive Opinion for Alnylams Patisiran for HATTR Amyloidosis Treatment ACCESSWIRE
Jul-30-18 12:36PM  Why Arrowhead Pharmaceuticals, Inc. Stock Slumped Today Motley Fool -7.37%
Jul-27-18 09:27AM  Alnylam to Webcast Conference Call Discussing Second Quarter 2018 Financial Results Business Wire
07:15AM  Alnylam Receives Positive CHMP Opinion for ONPATTRO (patisiran) for the Treatment of Hereditary Transthyretin-Mediated Amyloidosis in Adults with Stage 1 or Stage 2 Polyneuropathy Business Wire
Jul-23-18 07:00AM  Alnylam Presents New Analyses of Clinical Results from APOLLO Phase 3 Study of Patisiran at 2018 Peripheral Nerve Society Annual Meeting Business Wire
Jul-19-18 08:20AM  Today's Research Reports on Trending Tickers: Alnylam Pharmaceuticals and Endo International ACCESSWIRE
Jul-06-18 10:59AM  Analyst Downgrades Arbutus Biopharma On Valuation After 80% Run Benzinga
Jul-05-18 04:27PM  Why This Biotech Company 'Dominates' Its Rival In Drug Study Investor's Business Daily
Jul-04-18 05:10PM  Alnylam Announces Publication of APOLLO Phase 3 Clinical Study Results for Investigational RNAi Therapeutic Patisiran in The New England Journal of Medicine Business Wire
Jun-28-18 05:31PM  Medicines Company's Inclisiran Studies to Continue Unmodified Zacks
Jun-27-18 08:15AM  Report: Developing Opportunities within Valvoline, Parker Drilling, Dean Foods, BioPharmX, Hasbro, and Alnylam Pharmaceuticals Future Expectations, Projections Moving into 2018 GlobeNewswire
Jun-21-18 07:00AM  Alnylam to Host Fifth Annual RNAi Roundtable Webcast Series Business Wire
Jun-20-18 07:00AM  Alnylam Expands Senior Leadership Team with Two Key Appointments Business Wire
Jun-15-18 07:00AM  Alnylam to Report New Clinical Results for Patisiran at the 4th Congress of the European Academy of Neurology Business Wire
Jun-13-18 08:20AM  Today's Research Reports on Trending Tickers: Alnylam Pharmaceuticals and Intercept Pharmaceuticals ACCESSWIRE
Jun-12-18 08:00AM  Over 700 Alnylam Employees Volunteer at the Companys 4th Annual Helping Hands Community Service Day Business Wire +5.86%
07:30AM  Wired News Alnylam Pharma Presented New Encouraging Results from Phase-1/2 Study of Lumasiran in Patients with Primary Hyperoxaluria Type-1 ACCESSWIRE
Jun-11-18 04:49PM  Alnylam Reports Positive Data on Lumasiran in Renal Disease Zacks
07:10AM  Stock Performance Review on Alder Biopharma and Three Other Biotech Stocks ACCESSWIRE
Jun-08-18 07:00AM  Alnylam Reports Updated Positive Results from Phase 1/2 Study of Lumasiran in Patients with Primary Hyperoxaluria Type 1 (PH1) Business Wire
Jun-04-18 11:36AM  3 Top Biotech Stocks to Buy in June Motley Fool
07:00AM  Alnylam Receives Orphan Drug Designation from the United States Food & Drug Administration for ALN-TTRsc02, a Subcutaneously Delivered Investigational RNAi Therapeutic for the Treatment of Transthyretin-Mediated Amyloidosis Business Wire
06:25AM  Why Is Alnylam (ALNY) Up 12.6% Since Its Last Earnings Report? Zacks
Jun-03-18 07:17AM  Better Buy: Bellicum Pharmaceuticals, Inc. vs. Alnylam Pharmaceuticals, Inc. Motley Fool
May-29-18 07:00AM  Alnylam to Webcast Presentations at Upcoming June Investor Conferences Business Wire
May-17-18 06:32AM  Is Alnylam Pharmaceuticals, Inc. (ALNY) a Buy? Motley Fool
May-16-18 09:59AM  BioMarin Begins Mid Stage Study on Gene Therapy Candidate Zacks
May-15-18 07:00AM  Alnylam Appoints Colleen Reitan to the Board of Directors Business Wire
May-11-18 08:25AM  Consolidated Research: 2018 Summary Expectations for STORE Capital, Microvision, International Game Technology, McKesson, Marinus Pharmaceuticals, and Alnylam Pharmaceuticals Fundamental Analysis, Key Performance Indications GlobeNewswire
May-09-18 04:13AM  Edited Transcript of ALNY earnings conference call or presentation 3-May-18 8:30pm GMT Thomson Reuters StreetEvents
May-08-18 10:00AM  Alnylam Looks Forward Motley Fool
07:00AM  Alnylam Reports Preclinical Data Demonstrating Central Nervous System (CNS) Delivery of RNAi Therapeutics Business Wire
May-07-18 08:20AM  Today's Research Reports on Trending Tickers: Sarepta Therapeutics and Alnylam Pharmaceuticals ACCESSWIRE +5.49%
07:20AM  Blog Exposure - Alnylam Pharma Attained Alignment with FDA on Pivotal Study Design for Lumasiran for Treatment of Primary Hyperoxaluria Type 1 ACCESSWIRE
May-04-18 02:35PM  Alnylam's (ALNY) Q1 Loss Wider than Expected, Sales Miss Zacks
May-03-18 05:03PM  Alnylam: 1Q Earnings Snapshot Associated Press
04:00PM  Alnylam Pharmaceuticals Reports First Quarter 2018 Financial Results and Highlights Recent Period Activity Business Wire
07:00AM  Alnylam Achieves Alignment with FDA on Accelerated Development Path for Lumasiran, an Investigational RNAi Therapeutic for the Treatment of Primary Hyperoxaluria Type 1 (PH1) Business Wire
May-02-18 11:56AM  Boston biotech entrepreneur Christoph Westphal launches new startup American City Business Journals
May-01-18 04:00PM  Alnylam to Webcast Presentations at Upcoming May Investor Conferences Business Wire
Apr-26-18 04:00PM  Alnylam to Webcast Conference Call Discussing First Quarter 2018 Financial Results Business Wire
Apr-24-18 07:00AM  Alnylam Reports New Clinical Results from the APOLLO Phase 3 Study of Patisiran at the American Academy of Neurology 2018 Annual Meeting Business Wire
Apr-23-18 07:00AM  Alnylam Receives Positive Opinion for Orphan Drug Designation in the European Union for ALN-TTRsc02, a Subcutaneously Delivered Investigational RNAi Therapeutic for the Treatment of Transthyretin-Mediated Amyloidosis Business Wire
Apr-20-18 04:08PM  Why Dicerna Rocketed Higher Today Motley Fool
02:20PM  Dicerna to pay $27M to settle Alnylam trade secrets lawsuit American City Business Journals
01:55PM  U.S. biotech companies Alnylam, Dicerna settle trade secrets case Reuters
01:07PM  U.S. biotech companies Alnylam, Dicerna settle trade secrets case Reuters
01:03PM  UPDATE 1-U.S. biotech companies Alnylam, Dicerna settle trade secrets case Reuters
12:42PM  Alnylam Reaches Settlement Agreement with Dicerna Pharmaceuticals Resolving Trade Secret Misappropriation and Other Pending Litigation Business Wire
12:40PM  Biotech companies Alnylam, Dicerna settle trade secrets case Reuters
Apr-17-18 06:35PM  Alnylam (ALNY) Reports Positive Data for RNAi Candidate Zacks
Apr-14-18 01:00AM  Alnylam Presents New Positive Clinical Results for Givosiran, an Investigational RNAi Therapeutic for the Treatment of Acute Hepatic Porphyrias Business Wire
Apr-10-18 08:07AM  A Sixth Sense For Biotech Has Made Joe Edelman A Hedge Fund Star Forbes
Apr-06-18 12:55PM  The Week Ahead In Biotech: PDUFA Dates, IPOs And More Benzinga
Apr-03-18 03:30PM  How Worried Should Alnylam and Ionis Really Be About Pfizer's New Data? Motley Fool
10:10AM  Heres What Just Happened With Zosano Pharma Corporation And Pfizer Inc Market Exclusive
Apr-02-18 05:43PM  Alnylam Falls on Pfizer's Rare Disease Drug Success Zacks -15.05%
04:16PM  How Pfizer Sneaked Into Rare-Disease Market And Hit Alnylam, Ionis Investor's Business Daily
02:04PM  With Alnylam Pharma Down More Than 15%, Analyst Says Buy The Dip Benzinga
01:16PM  Benzinga's Top Analyst Calls From April 2, 2018 Benzinga
12:14PM  Why Alnylam Pharmaceuticals, Inc. Is Tanking Today Motley Fool
10:55AM  Why Pfizer's Big Win Is Bad News for Alnylam and Ionis Motley Fool
09:37AM  Pfizer's Rare Disease Candidate Meets Endpoint in Phase III Zacks
Mar-29-18 05:15PM  Pfizer Takes On Alnylam, Ionis With Rare Disease Treatment Investor's Business Daily -8.29%
Mar-28-18 04:00PM  Alnylam and Collaborators to Present Clinical Study Results in Acute Hepatic Porphyrias (AHPs) at The 53rd International Liver Congress of the European Association for the Study of the Liver (EASL) Business Wire
Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, discovers, develops, and commercializes novel therapeutics based on RNA interference (RNAi). Its pipeline of investigational RNAi therapeutics focuses on genetic medicines, cardio-metabolic diseases, and hepatic infectious diseases. The company's clinical development programs include Patisiran, which is in Phase III clinical trial for the treatment of hereditary transthyretin-mediated amyloidosis; Givosiran that is in Phase III trial to treat acute hepatic porphyrias; Fitusiran, an investigational RNAi therapeutic that is in Phase II open-label extension and Phase III clinical trial for the treatment of hemophilia and rare bleeding disorders; and Inclisiran, which is in III clinical trial for hypercholesterolemia. Its clinical programs also include ALN-TTRsc02, an investigational RNAi therapeutic targeting TTR, which is in the Phase I clinical trial for the treatment of various forms of ATTR amyloidosis; Lumasiran (ALN-GO1) that is in Phase I/II clinical trial for the treatment of primary hyperoxaluria type 1; and Cemdisiran (ALN-CC5), which is in the Phase II clinical trial for the treatment of complement-mediated diseases. The company has strategic alliances primarily with Sanofi Genzyme; The Medicines Company; Monsanto Company; Takeda Pharmaceutical Company Limited; Ionis Pharmaceuticals, Inc; and Regeneron Pharmaceuticals, Inc. Alnylam Pharmaceuticals, Inc. was founded in 2002 and is headquartered in Cambridge, Massachusetts.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
MARAGANORE JOHNChief Executive OfficerJul 25Option Exercise21.3550,0001,067,500201,297Jul 27 04:07 PM
MARAGANORE JOHNChief Executive OfficerJul 25Sale105.3950,0005,269,457151,297Jul 27 04:07 PM
KEATING LAURIESVP, GC & SecretaryJun 20Option Exercise42.221,56365,99016,063Jun 22 04:20 PM
KEATING LAURIESVP, GC & SecretaryJun 20Sale105.041,563164,17814,500Jun 22 04:20 PM
CLARKE JOHN KDirectorMay 31Option Exercise27.2815,000409,20023,891Jun 04 04:25 PM
CLARKE JOHN KDirectorMay 31Sale100.3115,0001,504,6788,891Jun 04 04:25 PM
Greenstreet YvonneEVP, Chief Operating OfficerMar 26Option Exercise42.227,221304,8717,221Mar 28 04:39 PM
Greenstreet YvonneEVP, Chief Operating OfficerMar 26Sale136.547,221985,9580Mar 28 04:39 PM
KEATING LAURIESVP, GC & SecretaryMar 20Option Exercise42.221,56265,94816,062Mar 22 06:18 PM
KEATING LAURIESVP, GC & SecretaryMar 20Sale149.831,562234,03314,500Mar 22 06:18 PM
Vaishnaw AkshayPresident, R&DMar 14Option Exercise17.0388,5541,507,84299,769Mar 16 05:05 PM
Vaishnaw AkshayPresident, R&DMar 14Sale143.1088,55412,672,12611,215Mar 16 05:05 PM
Greene Barry EPresidentMar 14Sale143.1038,4605,503,73661,968Mar 16 05:05 PM
SCHIMMEL PAULDirectorMar 13Option Exercise49.2427,8231,369,92727,823Mar 14 07:39 PM
KEATING LAURIESVP, GC & SecretaryMar 13Option Exercise77.4010,000774,00024,500Mar 14 07:40 PM
Ausiello Dennis ADirectorMar 13Option Exercise59.8217,1171,023,94217,117Mar 14 07:40 PM
SHARP PHILIP ADirectorMar 13Option Exercise21.3515,000320,250155,795Mar 14 07:39 PM
SHARP PHILIP ADirectorMar 13Sale149.0015,0002,235,000140,795Mar 14 07:39 PM
Ausiello Dennis ADirectorMar 13Sale150.0017,1172,567,5500Mar 14 07:40 PM
KEATING LAURIESVP, GC & SecretaryMar 13Sale150.0010,0001,500,00014,500Mar 14 07:40 PM
SCHIMMEL PAULDirectorMar 13Sale150.0027,8234,173,4500Mar 14 07:39 PM
KEATING LAURIESVP, GC & SecretaryMar 12Option Exercise77.4010,000774,00024,500Mar 14 07:40 PM
KEATING LAURIESVP, GC & SecretaryMar 12Sale140.0010,0001,400,00014,500Mar 14 07:40 PM
SHARP PHILIP ADirectorMar 09Option Exercise27.2815,000409,200155,795Mar 13 05:22 PM
SHARP PHILIP ADirectorMar 09Sale129.0015,0001,935,000140,795Mar 13 05:22 PM
Mason MichaelVP, Finance and TreasurerJan 04Option Exercise88.2631,7812,804,91136,745Jan 08 05:02 PM
Mason MichaelVP, Finance and TreasurerJan 04Sale131.5936,7454,835,1710Jan 08 05:02 PM
Mason MichaelVP, Finance and TreasurerDec 30Option Exercise0.008,50208,502Jan 03 05:26 PM
KEATING LAURIESVP, GC & SecretaryDec 29Option Exercise77.403,000232,20014,500Jan 03 05:13 PM
KEATING LAURIESVP, GC & SecretaryDec 20Option Exercise42.226,249263,83317,749Dec 21 05:00 PM
KEATING LAURIESVP, GC & SecretaryDec 20Sale121.206,249757,39811,500Dec 21 05:00 PM
MARAGANORE JOHNChief Executive OfficerDec 19Option Exercise63.001,58799,981151,297Dec 21 04:36 PM
KEATING LAURIESVP, GC and SecretaryDec 01Option Exercise77.4030,0002,322,00041,500Dec 05 05:47 PM
KEATING LAURIESVP, GC and SecretaryDec 01Sale135.8930,0004,076,82311,500Dec 05 05:47 PM
MARAGANORE JOHNChief Executive OfficerNov 22Option Exercise31.3973,4152,304,497223,125Nov 24 06:55 PM
MARAGANORE JOHNChief Executive OfficerNov 22Sale130.9073,4159,609,736149,710Nov 24 06:55 PM
MARAGANORE JOHNChief Executive OfficerNov 15Option Exercise31.3974,0002,322,860223,710Nov 17 05:35 PM
MARAGANORE JOHNChief Executive OfficerNov 15Sale126.8674,0009,387,951149,710Nov 17 05:35 PM
Ausiello Dennis ADirectorNov 02Option Exercise30.0920,000601,80020,000Nov 03 08:14 PM
Ausiello Dennis ADirectorNov 02Sale130.0020,0002,600,0000Nov 03 08:14 PM
Vaishnaw AkshayEVP, R&DOct 30Option Exercise21.3533,666718,76945,201Nov 01 05:33 PM
Vaishnaw AkshayEVP, R&DOct 30Sale121.4633,6664,088,96711,535Nov 01 05:33 PM
Greene Barry EPresidentOct 02Option Exercise21.3585,3161,821,497185,744Oct 04 07:45 PM
Greene Barry EPresidentOct 02Sale125.0085,31610,664,500100,428Oct 04 07:45 PM
Greene Barry EPresidentSep 21Option Exercise12.3311,844146,042100,428Sep 22 05:05 PM
Greene Barry EPresidentSep 20Option Exercise31.3976,8152,411,223165,399Sep 22 05:05 PM
Greene Barry EPresidentSep 20Sale100.0076,8157,681,50088,584Sep 22 05:05 PM